---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Asian ethnic bridging study"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Asian ethnic bridging study. Covers Objective, Study design, Eligibility criteria, Treatment, Study outcomes, Statistical analysis description, and 2 further headings. 17 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/asian-ethnic-bridging-study"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Asian ethnic bridging study

<a id="heading-3.1.8"></a>

## 3.1.8 Asian Ethnic Bridging Study

<a id="heading-3.1.8.1"></a>

### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

#### Primary and secondary objectives

> “Primary objective: To evaluate the pharmacokinetics (PK) of ESK-001 in Japanese, Chinese, and Caucasian healthy participants following single and multiple doses.”
> “Secondary objective: To assess the safety and tolerability of ESK-001 in Japanese, Chinese, and Caucasian healthy participants following single and multiple doses.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.2"></a>

### 3.1.8.2 Location and Study Date

No evidence found.

<a id="heading-3.1.8.3"></a>

### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

#### Sequential periods and blood sampling in the Japanese and Chinese cohorts

> “3 sequential treatment periods (Period 1: 20 mg single dose on Day 1; Period 2: 40 mg single dose on Day 6; Period 3: 40 mg BID for 7 days), each separated by 5-day washout periods.”
> “Blood samples collected on Days 1 and 2 for Period 1, on Days 6 and 7 for Period 2, and from Day 11 to Day 19 for Period 3.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.3-2"></a>

#### Caucasian reference cohort given the expected therapeutic dose only

> “1 treatment period (40 mg BID for 7 days).”
> “Note: Several previous ESK-001 studies (ClinPharm, STRIDE) have provided Caucasian data.”
> “Therefore, Cohort 3 was directly given the expected therapeutic dose (ie, 40 mg BID).”
> “Blood samples collected from Day 1 to Day 9.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.4"></a>

### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

#### Ancestry required for each cohort

> “Enrolled participants of Japanese and Chinese ancestry in Cohort 1 and Cohort 2, respectively.”
> “Enrolled participants of Caucasian ancestry.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.5"></a>

### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

#### Fed-state dosing in the Asian cohorts and fasted-state dosing in the Caucasian cohort on day 7 of twice-daily dosing

> “Note: Japanese & Chinese BID Day 7 PK profile is fed state and Caucasian BID Day 7 PK profile is fasted state dosing data.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.6"></a>

### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

#### 3.1.8.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

##### Noncompartmental analysis of the parent drug and its main metabolite

> “PK parameters were calculated from concentrations of ESK-001 (and its main metabolite) in plasma using noncompartmental analysis methods.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.6.1-2"></a>

##### Definitions of the steady-state pharmacokinetic parameters

> “Cmax,ss = maximum plasma concentration on Day 7 at steady state; AUC0-τ, ss = area under the concentration-time curve for the dosing interval at steady state; Tmax,ss= time needed to reach Cmax postdose on Day 7 at steady state; t1/2,ss = terminal elimination half-life on Day 7 at steady state; CL/F = apparent clearance; Vd/F = volume of distribution; BWCmax = body weight normalized Cmax; BWAUC = body weight normalized AUC; Rac = accumulation ratio; MRCmax = metabolite to parent ratio based on Cmax; MRAUC = metabolite to parent ratio based on AUC”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.7"></a>

### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

#### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

##### Single-center open-label enrollment of 24 participants in three cohorts

> “This Phase I, single-center, open-label study enrolled a total of 24 healthy participants (8 per cohort) into 1 of 3 cohorts.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.7.2"></a>

#### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

##### Descriptive statistics and external Caucasian data in the single-dose plots

> “The descriptive statistics shown are not log-transformed.”
> “Note: In 20 mg & 40 mg single dose graphs, Caucasian data was plotted with the data from another study (ie, ESK-001-003 20 mg QD/40 mg BID multiple dosing study).”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8"></a>

### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

#### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

##### Reason for the single discontinuation due to a treatment-emergent adverse event

> “Moderate headache that resolved with routine treatment (paracetamol) within 4 days of discontinuation of ESK-001”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8.2"></a>

#### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

##### Demographics by ethnic cohort

| Characteristic | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) | Overall (n=24) |
| --- | --- | --- | --- | --- |
| Age (years), mean (SD) | “42.6 (9.3)” | “38.4 (8.2)” | “45.5 (11.8)” | “42.2 (9.9)” |
| Sex, female/male, n (%) | “1 (12.5)/7 (87.5)” | “0 (0.0)/8 (100.0)” | “5 (62.5)/3 (37.5)” | “6 (25.0)/18 (75.0)” |
| Hispanic or Latino, n (%) | “0 (0.0)” | “0 (0.0)” | “2 (25.0)” | “2 (8.3)” |
| Not Hispanic or Latino, n (%) | “8 (100.0)” | “8 (100.0)” | “6 (75.0)” | “22 (91.7)” |
| Height (cm), mean (SD) | “170.2 (8.2)” | “170.0 (3.0)” | “168.6 (7.7)” | “169.6 (6.4)” |
| Weight (kg), mean (SD) | “66.4 (10.2)” | “72.6 (9.7)” | “80.4 (8.1)” | “73.1 (10.7)” |

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8.3"></a>

#### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

##### Steady-state pharmacokinetics of the parent drug and main metabolite on day 7 of 40 mg twice daily, by ethnic cohort

> “PK evaluation of ESK-001 and its main metabolite following 7th day of BID 40 mg oral administration of ESK-001”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

| Parameter | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) |
| --- | --- | --- | --- |
| Cmax,ss (ng/mL), geometric mean (CV%) | “502 (25.1)” | “586 (24.3)” | “531 (11.1)” |
| AUC0-τ,ss (hr*ng/mL), geometric mean (CV%) | “3,410 (22.7)” | “4,580 (18.3)” | “3,530 (9.5)” |
| Tmax,ss (hr), median (min, max) | “2.8 (2.0, 4.0)” | “3.0 (1.0, 6.0)” | “1.0 (1.0, 2.0)” |
| t1/2,ss (hr), geometric mean (CV%) | “7.6 (20.4)” | “8.4 (13.4)” | “9.1 (17.0)” |
| CL/F (L/hr), geometric mean (CV%) | “10.8 (22.7)” | “8.0 (18.3)” | “10.4 (9.5)” |
| Vd/F (L), geometric mean (CV%) | “118.0 (35.9)” | “97.4 (26.5)” | “138.0 (17.7)” |
| BWCmax (ng/mL/mg/kg), geometric mean (CV%) | “895 (32.5)” | “1,140 (14.3)” | “1,140 (12.6)” |
| BWAUC0-τ,ss (hr*ng/mL/mg/kg), geometric mean (CV%) | “6,080 (26.9)” | “8,950 (9.8)” | “7,540 (11.4)” |
| Rac, geometric mean (CV%) | “2.10 (96.3)” | “2.48 (38.0)” | “2.09 (34.7)” |
| MRCmax main metabolite, geometric mean (CV%) | “2.65 (33.6)” | “2.91 (23.1)” | “2.60 (24.9)” |
| MRAUC main metabolite, geometric mean (CV%) | “3.56 (30.3)” | “3.69 (24.9)” | “3.73 (15.8)” |

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.8.3-2"></a>

##### Comparability of absorption, exposure, elimination, and food effect across ethnicities

> “PK profiles of ESK-001 were similar across different ethnicities”
> “Rapid absorption, steady elimination, and dose-proportional exposure across all ethnicities.”
> “Food slightly delayed Tmax but did not significantly affect exposure.”
> “In general, plasma exposures (as Cmax and AUC) of ESK-001 and its main metabolite were comparable across ethnicities, as were elimination half-lives (t1/2), clearance (CL/F), and volume of distribution (Vd/F).”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.8.3-3"></a>

##### Conclusion on dosing in Asian populations

> “No clinically relevant differences in PK parameters, safety, or tolerability were observed across ethnicities, supporting the conclusion that the same therapeutic dosing regimen can be safely used for psoriasis treatment in Asian populations.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8.4"></a>

#### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

#### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

##### Treatment-emergent adverse events by dose period and ethnic cohort

| Event | 20 mg, Japanese (n=8) | 20 mg, Chinese (n=8) | 40 mg, Japanese (n=8) | 40 mg, Chinese (n=8) | 40 mg BID, Japanese (n=8) | 40 mg BID, Chinese (n=8) | 40 mg BID, Caucasian (n=8) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Any TEAE, n (%) | “1 (12.5)” | “2 (25.0)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “5 (62.5)” | “6 (75.0)” |
| At least 1 TEAE Grade 2, n (%) | “0 (0.0)” | “1 (12.5)” | “0 (0.0)” | “1 (12.5)” | “1 (12.5)” | “0 (0.0)” | “4 (50.0)” |
| At least 1 TEAE Grade ≥3, n (%) | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| TEAE related to study medication | “1 (12.5)” | “1 (12.5)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “4 (50.0)” | “6 (75.0)” |
| TEAEs leading to study discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |
| TEAEs leading to study medication discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.8.5-2"></a>

##### Tolerability, severity, and most common events by ethnic cohort

> “Safety profiles of ESK-001 were similar across different ethnicities”
> “ESK-001 was generally well tolerated at all evaluated doses.”
> “Most treatment-emergent adverse events (TEAEs) were mild, with some instances of moderate TEAEs.”
> “TEAEs related to ESK-001 were generally limited to expected TEAEs also observed during earlier clinical studies with ESK-001.”
> “Headache (Cohort 1: n=6; Cohort 2: n=3; Cohort 3: n=6)”
> “Somnolence (Cohort 1: n=4; Cohort 2: n=0; Cohort 3: n=0)”
> “Dizziness (Cohort 1: n=1; Cohort 2: n=2; Cohort 3: n=1”
> “No severe, life-threatening, or fatal TEAEs.”
> “No serious TEAEs or deaths.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.9"></a>

### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

#### Summary

- The only source is one congress poster; no registry record, study location, or study dates are quoted, and the poster states no limitations.
- The study was single-center and open-label, with 24 healthy participants (8 per cohort).
- The Caucasian cohort received only 40 mg BID, and the Caucasian single-dose curves were plotted with data from another study (ESK-001-003).
- Day 7 pharmacokinetic profiles of the twice-daily regimen were obtained in the fed state for the Japanese and Chinese cohorts and in the fasted state for the Caucasian cohort.
- The cohorts differed in sex (female/male: 1/7, 0/8, and 5/3) and mean weight (66.4, 72.6, and 80.4 kg), and the results are descriptive statistics that are not log-transformed.

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
